The phase 3 explorer7 study evaluated the efficacy and safety of concizumab, an anti-TFPI monoclonal antibody, for prophylaxis in patients with hemophilia A or B with inhibitors (HAwI/HBwI). The study included 133 male patients aged ≥12 years, with 80 having hemophilia A and 53 having hemophilia B. Patients were randomized in a 1:2 ratio to either no prophylaxis (group 1) or concizumab prophylaxis (group 2), with additional nonrandomized groups (3 and 4) receiving concizumab. After a minimum of 24 weeks, patients in the no prophylaxis group were allowed to switch to concizumab. At the 56-week cutoff, the primary endpoint showed a significant reduction in the median annualized bleeding rate (ABR) for spontaneous and traumatic bleeding episodes in patients receiving concizumab, with a median ABR of 0.8 (IQR, 0.0-3.2), consistent with earlier results at the 32-week cutoff. Secondary endpoints included pharmacokinetics and pharmacodynamics, which demonstrated stable concizumab and free-TFPI concentrations over time. Safety analysis revealed no new adverse events, confirming the drug's safety profile. The study results support the longer-term efficacy and safety of concizumab prophylaxis in reducing bleeding episodes in HAwI/HBwI patients, providing a viable prophylactic option for this population.
AI Accuracy Review: 9/10
· Auto-published
This study focuses on hemophilia, a condition where blood does not clot properly, leading to excessive bleeding. Researchers tested a new treatment called concizumab, which is given as an injection once a day, to see if it could help patients with hemophilia who have inhibitors—substances that make traditional treatments less effective. They found that patients receiving concizumab experienced much fewer bleeding episodes compared to those who did not receive any treatment. After a year, the results showed that concizumab was still effective and safe, with no new safety issues reported. This could mean that patients with hemophilia who have inhibitors might have a better quality of life with fewer bleeding problems. However, it's important to note that more research is needed to confirm these findings and to understand the long-term effects of this treatment.
What this means for you: Concizumab may greatly reduce bleeding for hemophilia patients with inhibitors and is safe for long-term use.
View Original Abstract ↓
Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody intended for once-daily subcutaneous prophylactic treatment for people with hemophilia A or B with and without inhibitors. Results from the phase 3 explorer7 study confirmed superiority of concizumab prophylaxis over no prophylaxis in reducing the annualized bleeding rate (ABR) in people with hemophilia A or B with inhibitors (HAwI/HBwI). Male patients aged ≥12 years were randomized 1:2 to no prophylaxis (group 1) or concizumab prophylaxis (group 2), or nonrandomly allocated to concizumab prophylaxis (groups 3 and 4). After ≥24 weeks of treatment, patients in group 1 could switch to concizumab prophylaxis. At the 56-week cutoff (defined as when all patients in groups 2-4 had completed the visit at 56 weeks or permanently discontinued treatment), bleed-related efficacy, pharmacokinetics and pharmacodynamics, and safety were assessed. Of the 133 patients enrolled (HAwI, n = 80; HBwI, n = 53), 114 received concizumab prophylaxis (groups 2-4) and 19 were randomized to no prophylaxis (group 1). After ≥24 weeks, 13 patients from group 1 switched to concizumab. Median ABR for treated spontaneous and traumatic bleeding episodes in patients receiving concizumab was 0.8 (interquartile range [IQR], 0.0-3.2) at the 56-week cutoff, consistent with the low bleeding rates (median ABR, 0.0; IQR, 0.0-3.3) at the 32-week cutoff. Concizumab and free-TFPI concentration remained stable over time. No new safety concerns were reported. Longer-term (≥1 year) efficacy and safety results of concizumab prophylaxis for HAwI/HBwI were consistent with the 32-week cutoff results in explorer7. This trial was registered at www.clinicaltrials.gov as #NCT04083781.